J 2020

Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)

NEMEJCOVA, K., R. KOCIAN, C. KOHLER, Jiří JARKOVSKÝ, J. KLAT et. al.

Basic information

Original name

Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)

Authors

NEMEJCOVA, K. (203 Czech Republic), R. KOCIAN (203 Czech Republic), C. KOHLER (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), J. KLAT (203 Czech Republic), A. BERJON (724 Spain), R. PILKA (203 Czech Republic), B. SEHNAL (203 Czech Republic), B. GIL-IBANEZ (724 Spain), E. LUPO (32 Argentina), A. PETIZ (620 Portugal), O. A. SANCHEZ (724 Spain), P. KASCAK (703 Slovakia), F. MARTINELLI (380 Italy), A. BUDA (380 Italy), J. PRESL (203 Czech Republic), M. BARAHONA (724 Spain), L. VAN LONHUIJZEN (528 Netherlands), W. SZATKOWSKI (616 Poland), Luboš MINÁŘ (203 Czech Republic, belonging to the institution), M. PAKIZ (703 Slovakia), P. HAVELKA (203 Czech Republic), C. ZORRERO (724 Spain), M. MISIEK (616 Poland), L. C. SNYMAN (710 South Africa), D. WYDRA (616 Poland), I. VERGOTE (56 Belgium), A. VINNYTSKA (804 Ukraine), M. REDECHA (703 Slovakia), M. MICHAL (203 Czech Republic), S. TINGULSTAD (578 Norway), B. KIPP (756 Switzerland), G. SZEWCZYK (616 Poland), R. TOTH (703 Slovakia), F. J .D. GARCIA (724 Spain), P. J. C. MARTIN (724 Spain), R. POKA (348 Hungary), K. TAMUSSINO (40 Austria), M. LUYCKX (56 Belgium), M. FASTREZ (56 Belgium), J. C. STARINGER (32 Argentina), A. GERMANOVA (203 Czech Republic), A. PLAIKNER (276 Germany), S. BAJSOVA (203 Czech Republic), P. DUNDR (203 Czech Republic), N. MALLMANN-GOTTSCHALK (276 Germany) and D. CIBULA (203 Czech Republic, guarantor)

Edition

Cancers, BASEL, MDPI, 2020, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 6.639

RIV identification code

RIV/00216224:14110/20:00116028

Organization unit

Faculty of Medicine

UT WoS

000539246000056

Keywords in English

sentinel lymph node; cervical cancer; metastases

Tags

International impact, Reviewed
Změněno: 12/5/2021 13:16, Mgr. Tereza Miškechová

Abstract

V originále

The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.